PTC Therapeutics
PTCT
63.23
-0.47
-0.74%
PTC Therapeutics
US · PTCT
#2071 by market cap
Listed 1970
63.23
-0.47
-0.74%
Live - 5344 symbols - heartbeat 421s ago
· 2026-10-07 19:54
After-hours
63.23
0.00%
- Market cap
- 5.28B
- P/E (TTM)i
- -103.66
- P/Bi
- -31.92
- EPSi
- 7.78
- Div yieldi
- 0.00%
- 52W posi
- 7%
Reader sentiment
Are you bullish or bearish on PTCT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.70, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +114.51% YoY
Margins
- Gross margin
- 97.28%
- Operating margin
- 49.49%
- Net margin
- 39.44%
Key ratios & quality
- Enterprise valuei
- 5.94B
- Altman Z-Scorei
- 1.70
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 264.73M | 306.98M | 380.77M | 538.59M | 698.80M | 937.82M | 806.78M | 1.73B |
| Gross profit | 252.06M | 294.85M | 361.82M | 506.27M | 654.12M | 872.34M | 749.38M | 1.68B |
| Selling & admin expenses | 153.55M | 202.54M | 245.16M | 285.77M | 326.00M | 332.54M | 300.91M | 347.14M |
| Research & development | 171.98M | 257.45M | 477.64M | 540.68M | 651.50M | 666.56M | 534.48M | 455.25M |
| Operating profit | -96.35M | -192.80M | -397.88M | -374.94M | -439.93M | -349.40M | -146.75M | 856.51M |
| Pretax profit | -128.11M | -239.93M | -402.93M | -518.34M | -587.49M | -696.11M | -363.12M | 696.62M |
| Tax | -29.00K | 11.65M | 35.23M | 5.56M | -28.47M | -69.51M | 176.00K | 13.98M |
| Net profit | -128.08M | -251.58M | -438.16M | -523.90M | -559.02M | -626.60M | -363.30M | 682.64M |
| Basic EPS | -3 | -4 | -7 | -7 | -8 | -8 | -5 | 9 |
| Diluted EPS | -2.75 | -4.27 | -6.64 | -7.43 | -7.79 | -8.37 | -4.73 | 8.58 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.18B | 178.88M | 211.01M | 164.68M | 272.55M | 360.52M |
| Gross profit | 1.16B | 167.46M | 195.23M | 157.73M | 244.52M | 340.60M |
| Selling & admin expenses | 80.96M | 85.26M | 84.05M | 96.87M | 86.18M | 80.63M |
| Research & development | 108.97M | 112.99M | 100.16M | 133.13M | 100.87M | 99.15M |
| Operating profit | 969.50M | -34.86M | 3.49M | -81.62M | 45.89M | 148.98M |
| Pretax profit | 929.83M | -71.05M | -23.07M | -139.08M | -2.46M | 97.55M |
| Tax | 63.27M | -6.20M | -38.97M | -4.12M | 347.00K | 14.05M |
| Net profit | 866.56M | -64.85M | 15.90M | -134.97M | -2.81M | 83.50M |
| Basic EPS | 11 | -1 | 0 | -2 | 0 | 1 |
| Diluted EPS | 10.04 | -0.83 | 0.20 | -1.67 | -0.03 | 0.92 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 320.86M | 779.28M | 1.23B | 954.37M | 693.79M | 1.22B | 1.37B | 2.27B |
| Cash & ST investments | 227.59M | 686.56M | 1.10B | 773.38M | 410.71M | 876.74M | 1.14B | 1.95B |
| Inventory | 16.12M | 19.29M | 18.70M | 15.86M | 21.81M | 30.58M | 23.19M | 79.65M |
| Total assets | 1.12B | 1.62B | 2.21B | 1.94B | 1.71B | 1.90B | 1.71B | 2.90B |
| Total current liabilities | 166.80M | 235.86M | 277.33M | 509.35M | 406.24M | 603.10M | 580.98M | 968.43M |
| Short-term debt | 11.67M | 25.15M | 8.74M | 219.10M | 84.52M | 210.32M | 271.18M | 585.12M |
| Long-term debt | 141.35M | 293.86M | 309.15M | 956.59M | 1.26B | 1.90B | 2.11B | 2.03B |
| Total liabilities | 768,495,000.00 | 1,029,452,000.00 | 1,726,296,000.00 | 1,936,618,000.00 | 2,052,705,000.00 | 2,714,253,000.00 | 2,803,095,000.00 | 3,104,080,000.00 |
| Total equity | 350.73M | 594.33M | 481.98M | 1.44M | -347.09M | -818.56M | -1.10B | -205.31M |
| Retained earnings | -938.92M | -1.19B | -1.63B | -2.10B | -2.66B | -3.28B | -3.65B | -2.96B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 2.32B | 2.27B | 2.01B | 2.27B | 2.25B | 2.62B |
| Cash & ST investments | 2.03B | 1.99B | 1.69B | 1.95B | 1.89B | 2.23B |
| Inventory | 21.68M | 34.06M | 52.69M | 79.65M | 75.57M | 91.35M |
| Total assets | 2.66B | 2.63B | 2.64B | 2.90B | 2.87B | 3.25B |
| Total current liabilities | 595.39M | 627.81M | 866.25M | 968.43M | 923.60M | 771.07M |
| Short-term debt | 16.51M | 17.08M | 300.81M | 585.12M | 305.02M | 73.42M |
| Long-term debt | 285.71M | 286.01M | -- | 2.03B | -- | 535.52M |
| Total liabilities | 2,841,147,000.00 | 2,840,701,000.00 | 2,799,458,000.00 | 3,104,080,000.00 | 3,049,569,000.00 | 3,415,840,000.00 |
| Total equity | -185.76M | -206.55M | -155.76M | -205.31M | -180.47M | -165.36M |
| Retained earnings | -2.78B | -2.85B | -2.83B | -2.96B | -2.97B | -2.88B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -27.64M | -98.64M | -194.07M | -251.33M | -356.65M | -158.42M | -107.69M | 711.20M |
| Depreciation & amortization | 26.09M | 32.18M | 43.49M | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| Free cash flow | -43.17M | -144.08M | -250.05M | -336.66M | -509.11M | -279.04M | -181.94M | 411.18M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 117.92M | 323.76M | 28.09M | 0 | 50.00M | -- | -- | -- |
| Ending cash balance | 169.50M | 295.53M | 216.31M | 197.22M | 295.93M | 610.28M | 795.32M | 998.33M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 870.10M | -58.33M | -66.30M | -34.27M | -59.04M | 129.11M |
| Depreciation & amortization | 7.22M | 7.58M | 11.11M | 12.90M | 15.41M | 15.87M |
| Free cash flow | 867.57M | -62.26M | -322.57M | -71.56M | -60.40M | 121.97M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.50B | 1.03B | 686.30M | 998.33M | 850.44M | 1.07B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -50.51 | -53.24 | -81.42 | -216.75 | -- | -- | -- | -- |
| ROA %i | -16.95 | -18.34 | -22.87 | -25.27 | -30.68 | -34.80 | -20.18 | 29.66 |
| ROIC %i | -31.36 | -35.64 | -43.86 | -64.08 | -- | -- | -- | -- |
| 5-year avg ROE %i | -59.62 | -61.65 | -64.93 | -91.83 | -- | -- | -- | -- |
| EBIT margin %i | -36.39 | -62.80 | -91.02 | -80.27 | -71.07 | -60.45 | -24.31 | 49.05 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | 23.76 |
| Current ratioi | 1.92 | 3.30 | 4.44 | 1.87 | 1.71 | 2.02 | 2.35 | 2.35 |
| Quick ratioi | 1.77 | 3.15 | 4.23 | 1.74 | 1.39 | 1.72 | 2.23 | 2.20 |
| Debt / assetsi | 13.67 | 20.20 | 19.04 | 65.50 | 85.69 | 117.59 | 144.93 | 93.39 |
| LT debt / equityi | 40.30 | 50.96 | 85.42 | 73,036.16 | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -6.15 | -5.03 | -5.47 | -4.39 | -1.17 | 5.58 |
| Revenue CAGR (3Y) %i | 93.10 | 54.83 | 25.12 | 26.71 | 31.55 | 35.05 | 14.42 | 35.30 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | 26.76 | 27.65 | 33.51 | 29.66 | -6.76 | -1.30 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 45.78 | 46.08 | 49.41 | 49.05 | -8.28 | 11.72 |
| FCF / sales %i | 38.31 | 38.58 | 25.08 | 23.76 | -- | -- |
| Current ratioi | 3.89 | 3.62 | 2.32 | 2.35 | 2.44 | 3.39 |
| Quick ratioi | 3.76 | 3.48 | 2.18 | 2.20 | 2.29 | 3.20 |
| Debt / assetsi | 14.67 | 14.74 | 15.51 | 93.39 | 13.77 | 21.43 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 5.06 | 5.53 | 6.37 | 5.58 | -0.41 | 0.64 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Sephience is the largest reported line at 41.97% of revenue, across 7 reported segments.
- No single line clears half of revenue; Royalty revenue is next at 19.72%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Sephience41.97%
Royalty revenue19.72%
Collaboration and license revenue14.03%
Translarna11.71%
Emflaza6.83%
Upstaza/Kebilidi3.10%
All other products2.63%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.